Sign In
Buy RYLPF
Koninklijke Philips N.V Earnings Calls
| Release date | May 06, 2026 |
| EPS estimate | $0.234 |
| EPS actual | $0.266 |
| EPS Surprise | 13.60% |
| Revenue estimate | 4.48B |
| Revenue actual | 4.512B |
| Revenue Surprise | 0.709% |
| Release date | Feb 10, 2026 |
| EPS estimate | $0.564 |
| EPS actual | $0.705 |
| EPS Surprise | 25.00% |
| Revenue estimate | 5.889B |
| Revenue actual | 5.986B |
| Revenue Surprise | 1.65% |
| Release date | Nov 04, 2025 |
| EPS estimate | $0.366 |
| EPS actual | $0.224 |
| EPS Surprise | -38.84% |
| Revenue estimate | 5.033B |
| Revenue actual | 5.039B |
| Revenue Surprise | 0.115% |
| Release date | Jul 29, 2025 |
| EPS estimate | $0.316 |
| EPS actual | $0.295 |
| EPS Surprise | -6.64% |
| Revenue estimate | 4.304B |
| Revenue actual | 5.108B |
| Revenue Surprise | 18.67% |
Last 4 Quarters for Koninklijke Philips N.V
Below you can see how RYLPF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jul 29, 2025 |
| Price on release | $28.00 |
| EPS estimate | $0.316 |
| EPS actual | $0.295 |
| EPS surprise | -6.64% |
| Date | Price |
|---|---|
| Jul 23, 2025 | $23.85 |
| Jul 24, 2025 | $26.01 |
| Jul 25, 2025 | $25.74 |
| Jul 28, 2025 | $25.69 |
| Jul 29, 2025 | $28.00 |
| Jul 30, 2025 | $28.00 |
| Jul 31, 2025 | $28.00 |
| Aug 01, 2025 | $28.00 |
| Aug 04, 2025 | $26.50 |
| 4 days before | 17.41% |
| 4 days after | -5.38% |
| On release day | 0% |
| Change in period | 11.10% |
| Release date | Nov 04, 2025 |
| Price on release | $27.65 |
| EPS estimate | $0.366 |
| EPS actual | $0.224 |
| EPS surprise | -38.84% |
| Date | Price |
|---|---|
| Oct 29, 2025 | $26.87 |
| Oct 30, 2025 | $26.84 |
| Oct 31, 2025 | $27.65 |
| Nov 03, 2025 | $27.65 |
| Nov 04, 2025 | $27.65 |
| Nov 05, 2025 | $27.65 |
| Nov 06, 2025 | $27.65 |
| Nov 07, 2025 | $27.70 |
| Nov 10, 2025 | $27.65 |
| 4 days before | 2.89% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 2.89% |
| Release date | Feb 10, 2026 |
| Price on release | $33.00 |
| EPS estimate | $0.564 |
| EPS actual | $0.705 |
| EPS surprise | 25.00% |
| Date | Price |
|---|---|
| Feb 04, 2026 | $29.16 |
| Feb 05, 2026 | $29.16 |
| Feb 06, 2026 | $29.16 |
| Feb 09, 2026 | $29.28 |
| Feb 10, 2026 | $33.00 |
| Feb 11, 2026 | $33.00 |
| Feb 12, 2026 | $33.00 |
| Feb 13, 2026 | $33.00 |
| Feb 17, 2026 | $33.00 |
| 4 days before | 13.17% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 13.17% |
| Release date | May 06, 2026 |
| Price on release | $26.31 |
| EPS estimate | $0.234 |
| EPS actual | $0.266 |
| EPS surprise | 13.60% |
| Date | Price |
|---|---|
| Apr 30, 2026 | $27.75 |
| May 01, 2026 | $26.05 |
| May 04, 2026 | $26.05 |
| May 05, 2026 | $26.05 |
| May 06, 2026 | $26.31 |
| May 07, 2026 | $26.93 |
| May 08, 2026 | $26.93 |
| May 11, 2026 | $26.93 |
| May 12, 2026 | $26.93 |
| 4 days before | -5.19% |
| 4 days after | 2.35% |
| On release day | 2.35% |
| Change in period | -2.96% |
Koninklijke Philips N.V Earnings Call Transcript Summary of Q1 2026
Philips delivered a solid start to 2026: Q1 order intake +6% and comparable sales +3.7% (personal health +9%), with broad-based growth led by North America. Adjusted EBITDA margin expanded 40 bps to 9% (sixth consecutive quarter of progress) driven by sales growth, innovation-led higher gross margin and productivity (Q1 productivity savings €126m; on track for €1.5bn 3‑year target). Key innovation highlights include BlueSeal helium‑free MRI traction and a 3.0T roadmap, Verida spectral CT initial orders and installation, FDA clearances for AI solutions (SmartHeart, DeviceGuide) and ongoing clinical studies for the interventional platform. Connected Care monitoring and enterprise informatics momentum continues, with growing enterprise monitoring-as-a-service wins. Personal Health outperformed with strong retail distribution expansion and new product adoption. Cash was €2.6bn after the SpectraWAVE acquisition; net debt €5.5bn and leverage ~1.8x. Management reiterated full‑year guidance: comparable sales +3.0–4.5%, adjusted EBITDA margin 12.5–13.0% and free cash flow €1.3–1.5bn. Risks called out: geopolitical developments in the Middle East, tariff and input cost inflation (freight, components, plastics), and China centralized procurement pressuring certain modalities (CT, ultrasound). Management expects to offset inflationary pressures via supply‑chain optimization, productivity, selective pricing and tariff developments, but expects some near‑term margin pressure and back‑loaded mitigation benefits.
